Goldman Sachs Group Inc Iveric Bio, Inc. Transaction History

Goldman Sachs Group Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 14, 2024	BUY	$26.24 - $39.63 $84.6 Million - $128 Million	3,225,818 Added 323.73%	4,222,280 $166 Million
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $84.6 Million - $128 Million	3,225,818 Added 323.73%	4,222,280 $166 Million
Q1 2023 May 14, 2024	SELL	$18.67 - $24.56 $5.25 Million - $6.9 Million	-280,962 Reduced 21.99%	996,462 $24.2 Million
Q1 2023 May 11, 2023	SELL	$18.67 - $24.56 $5.25 Million - $6.9 Million	-280,962 Reduced 21.99%	996,462 $24.2 Million
Q4 2022 May 14, 2024	BUY	$17.24 - $23.95 $4.73 Million - $6.57 Million	274,126 Added 27.32%	1,277,424 $27.3 Million

Q4 2022 Feb 13, 2023	BUY	$17.24 - $23.95 $4.73 Million - $6.57 Million	274,126 Added 27.32%	1,277,424 $27.3 Million
Q3 2022 May 14, 2024	BUY	$9.4 - $18.59 $2.26 Million - $4.47 Million	240,487 Added 31.53%	1,003,298 $18 Million
Q3 2022 Nov 10, 2022	BUY	$9.4 - $18.59 $2.26 Million - $4.47 Million	240,487 Added 31.53%	1,003,298 $18 Million
Q2 2022 May 14, 2024	BUY	$9.12 - $18.9 $6.96 Million - $14.4 Million	762,811 New	762,811 $7.34 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $3.12 Million - $6.47 Million	342,115 Added 81.32%	762,811 $7.34 Million
Q1 2022 May 16, 2022	BUY	$12.15 - $16.83 $86,896 - $120,368	7,152 Added 1.73%	420,696 $7.08 Million
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $3.17 Million - $4.3 Million	229,057 Added 124.16%	413,544 $6.91 Million
Q3 2021 Nov 10, 2021	BUY	$7.07 - $17.5 $1.3 Million - $3.23 Million	184,487 New	184,487 $3 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.